FGL1 and breast carcinoma: Gong et al. demonstrated that in breast cancer, the use of nanoparticle-encapsulated si-FGL1 can enhance the anti-tumor immune effect mediated by T cells, and the use of nanoparticles to simultaneously block FGL1 and PD-L1 is effective in enhancing T cell anti-tumor ability and has obvious synergistic effects (15).